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Background: Cardiovascular magnetic resonance (CMR) can provide important diagnostic and prognostic
information in patients with heart failure. However, in the current health care environment, use of a new imaging
modality like CMR requires evidence for direct additive impact on clinical management. We sought to evaluate the
impact of CMR on clinical management and diagnosis in patients with heart failure.
Methods: We prospectively studied 150 consecutive patients with heart failure and an ejection fraction ≤50%
referred for CMR. Definitions for “significant clinical impact” of CMR were pre-defined and collected directly from
medical records and/or from patients. Categories of significant clinical impact included: new diagnosis, medication
change, hospital admission/discharge, as well as performance or avoidance of invasive procedures (angiography,
revascularization, device therapy or biopsy).
Results: Overall, CMR had a significant clinical impact in 65% of patients. This included an entirely new diagnosis in
30% of cases and a change in management in 52%. CMR results directly led to angiography in 9% and to the
performance of percutaneous coronary intervention in 7%. In a multivariable model that included clinical and
imaging parameters, presence of late gadolinium enhancement (LGE) was the only independent predictor of
“significant clinical impact” (OR 6.72, 95% CI 2.56-17.60, p=0.0001).
Conclusions: CMR made a significant additive clinical impact on management, decision-making and diagnosis in 65%
of heart failure patients. This additive impact was seen despite universal use of prior echocardiography in this patient
group. The presence of LGE was the best independent predictor of significant clinical impact following CMR.Background
Cardiovascular magnetic resonance (CMR) is emerging
as a powerful diagnostic tool capable of assessing a wide
array of important variables in heart failure [1,2], including
cardiac structure, function, viability, scar pattern, perfusion,
and the presence of thrombus [3-10].The versatility of
CMR in assessing the etiology and prognosis of cardio-
myopathies makes it a potentially valuable adjunct to
traditional imaging modalities [11].
Current guidelines from the Heart Failure Society of
America recommend using CMR in the diagnosis of* Correspondence: afshin@uic.edu
2Section of Cardiology, Department of Medicine, University of Illinois at
Chicago, 840 South Wood St. M/C 715, Suite 920 S, Chicago, IL 60612, USA
5Department of Radiology, University of Illinois at Chicago, Chicago, IL, USA
Full list of author information is available at the end of the article
© 2013 Abbasi et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the oramyloidosis, sarcoidosis, hemochromatosis, and possibly
in viability assessment. However, there is no particular
recommendation for its use in initial evaluation of heart
failure [12]. In the current health care environment, use of
a new imaging modality like CMR requires evidence
for direct additive impact on clinical management. We
hypothesized that findings on CMR would significantly
alter management, clinical decision-making and diagnoses
in patients referred from an advanced heart failure pro-
gram. Furthermore, we sought to assess which findings on
CMR best predict subsequent clinical impact.
Methods
Study protocol
This was a prospective observational study from an aca-
demic medical center in the United States with anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://jcmr-online.com/content/15/1/89established heart failure program. We studied 150 con-
secutive patients referred for CMR from the heart failure
program over a period of 6-months. Patients were included
if they had an LVEF≤50% by prior imaging studies. CMR
was performed by standardized protocols recommended by
the Society of Cardiovascular Magnetic Resonance (SCMR)
[13] on 1.5T or 3T scanners and interpreted by an experi-
enced reader (AF). The CMR protocol included ventricular
function assessment (by a standard steady-state free preces-
sion sequence obtained in short and long-axis views) and
late gadolinium enhancement (LGE) imaging obtained
10-15 minutes after administration of intravenous gadolin-
ium (0.15 mmol/kg), as per published guidelines [13]. The
presence and location of LGE was determined by visual in-
spection using the AHA 17-segment model [14]. Regional
enhancement was scored according to the spatial extent of
enhanced tissue within each segment (0 = no enhancement;
1 = 1%–25% enhanced; 2 = 26%–50%; 3 = 51%–75%; and
4 = 76%–100%) [14]. The pattern of enhancement was
classified as either Coronary Artery Disease (CAD)-type or
non-CAD-type on the basis of subendocardial involvement
[15,16]. Demographic and clinical characteristics were
recorded at the time of CMR, including age, gender, New
York Heart Association (NYHA) functional class, left ven-
tricular ejection fraction (LVEF), medications, previous car-
diac imaging, and referral indications. The study was
approved by the local institutional review board, and all
subjects gave written informed consent.
Influence of CMR on subsequent clinical management
Definitions for “significant clinical impact” of CMR were
pre-defined and were collected directly from medical re-
cords or patient interview (Figure 1). Data was collectedFigure 1 Definition of Significant Clinical Impact. PCI=percutaneous co
ICD=implantable cardioverter-defibrillator.and interpreted by one of the primary investigators in all
cases. Another physician, unaffiliated with the CMR or
heart failure programs, independently interpreted a ran-
domly generated sample of the patients. This physician was
blinded to the previous interpretations of “significant clin-
ical impact.” A third independent physician adjudicated any
discrepancy between the interpreters.
Significant clinical impact
“Significant Clinical Impact” was defined as an entirely
“new diagnosis” or if a “change in management” occurred
(see definitions below and Figure 1). A patient with both a
new diagnosis and a change in management (e.g. CMR
findings led to the new diagnosis of hypertrophic cardiomy-
opathy and the patient received an ICD) was only counted
once toward “significant clinical impact.”
New diagnosis
A “new diagnosis” was defined as occurring only if it
was previously unknown by the referring physician. For
example, a patient who had a CMR for assessment of
iron overload but was found instead to have evidence of
myocardial infarction would be defined as having had a
new diagnosis (Figure 2).
Change in management
“Change in Management” was defined as occurring if one
of the following criteria were met: CMR results led directly
to the performance of or avoidance of an invasive proced-
ure (endomyocardial biopsy, angiography, PCI, CABG, or
ICD placement); CMR findings led to the initiation or dis-
continuation of a cardiac medication; CMR results led to
the initiation or cessation of systemic anticoagulation; orronary intervention; CABG=coronary artery bypass grafting;
Figure 2 Example of a New Diagnosis. A 32 year-old woman with
sickle cell anemia was referred for evaluation of iron overload by
T2* imaging, which was normal. However, nearly transmural
hyperenhancement (white arrows) was seen in the apical inferior
wall on late enhancement imaging, indicative of previously
unrecognized myocardial infarction.
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http://jcmr-online.com/content/15/1/89CMR findings directly resulted in hospital admission or
discharge (Figure 1). A patient whose management was
changed in more than one category (e.g. CMR findings
led to the new diagnosis of intracardiac thrombus and
the patient was subsequently admitted to the hospital
for intravenous anticoagulation) was only counted once
toward “significant clinical impact” (Figure 3).Figure 3 Example of a Change in Management. A 65 year-old man w
testing. CMR unexpectedly revealed a large apical thrombus, for which t
systemic anticoagulation.Statistical analysis
Normally distributed data are presented as the mean ± SD.
Continuous covariates were compared by Student’s t-test
or Wilcoxon rank-sum (depending on data normality).
Fishers exact test was used to compare discrete data be-
tween groups. To identify which clinical and CMR indices
were associated with a “significant clinical impact”, we
performed univariable (unadjusted) logistic regression
analysisto estimate the unadjusted odds ratios (OR) and the
95% confidence intervals (CIs) for the following variables:
age, gender, NYHA class,diabetes, hypertension, prior
revascularization, LVEF and presence of LGE. For the
multivariable model, candidate variables showing a possible
association with “significant clinical impact” by univariable
analysis (p < 0.10) were considered one-at-a-time starting
with the most significant variable. Significant variables
were determined by stepwise selection (and backward
elimination) at the 0.05 level of significance. All analyses
were performed in MedCalc (version 12.3, New York City,
NY) or SAS (version 9.3, SAS Institute, Cary, NC).Results
Baseline clinical characteristics
Mean age was 54 years, with 57% of patients being men
(Table 1). The mean LVEF was 38% (±11%). A 3.0 Tesla
magnet was used in 51% of the studies. All patients had a
recent echocardiogram prior to their CMR study. Of the 20
patients randomly selected for secondary review by an
interpreter unaffiliated with the CMR and heart failure pro-
grams, there was only one instance of discrepant interpret-
ation. A third independent physician adjudicated the
discrepancy in this single case. Image quality was qualita-
tively assessed as good vs poor at the time of reading. Over-
all there were 7 patients (5% of cohort) with poor imageas referred for assessment of ventricular function and viability
he patient was admitted to hospital for initiation of
Table 1 Study Population
Baseline characteristics
Sex
Male 57%
Female 43%
Age (years±SD) 54 (±17)
Family history of dilated cardiomyopathy 10%
Family history of CAD 18%
NYHA class
I 26%
II 49%
III 24%
IV 1%
Ejection fraction (±SD) 38% (±11%)
History of alcohol excess 7%
Preceding flu-like illness 8%
Comorbidities
Diabetes 28%
Hypertension 75%
Atrial fibrillation 17%
Muscular dystrophy 3%
Prior revascularizations
CABG 7%
PCI 29%
Cardiac diagnostics
Prior SPECT 18%
Prior echocardiogram 100%
Prior coronary angiogram 59%
Referral indications
Assessment of cardiomyopathy of unknown
etiology
59%
Assessment of viability 31%
Assessment of suspected myocarditis 5%
Other 5%
CAD=Coronary artery disease; NYHA=New york heart association;
PCI=Percutaneous coronary intervention; CABG=Coronary artery bypass
grafting; SPECT=Single photon emission computed tomography.
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4 patients had atrial fibrillation. Overall 17% (26 patients) of
the total cohort had atrial fibrillation and image quality was
assessed as good in the majority of these (22 cases or 85%).Indications for CMR
The most common referral indications were for assess-
ment of: 1) cardiomyopathy of unknown etiology, 2) via-
bility, 3) suspected myocarditis (Table 1).New diagnoses
An entirely new diagnosis was found in 30% of cases
(Figure 4). The most frequently discovered new diagno-
ses were non-ischemic cardiomyopathy – based on scar
pattern (found in 7% of all cases, accounting for 24% of
new diagnoses), left-ventricular thrombus (found in 6.7%
of all cases, accounting for 22% of new diagnoses), and
coronary artery disease (found in 5% of all cases, ac-
counting for 16% of new diagnoses). Rarer diagnoses in-
cluded myocarditis and muscular dystrophy related
cardiomyopathy. The patients that were diagnosed with
myocarditis had a flu like prodrome with chest pain, ele-
vated cardiac enzymes, normal or non-obstructive coron-
ary arteries on angiography and a mid-myocardial or
epicardial LGE pattern on CMR [17]. The patients that
were diagnosed with muscular dystrophy related cardio-
myopathy had a known neurological diagnosis of muscu-
lar dystrophy and were found to have midwall or
epicardial LGE on CMR in the basal inferior and/or
infero-lateral walls [18]. Overall, in more than half of cases
(57%), the discovery of a new diagnosis led to a change in
patient management.
Change in management
The results of a patient’s CMR led to a change in manage-
ment in a variety of ways (Table 2). The most commonly
impacted elements of patient care were catheter-based pro-
cedures, where 27% of patients had their care affected dir-
ectly as a result of CMR findings (Table 2). CMR results led
to angiography in 9% of cases and led to the avoidance of
angiography in 11% of cases. CMR findings led to PCI in
7% of patients and led to the avoidance of PCI in 5% of
cases. CMR findings also had significant impact on the role
of surgical revascularization, where the results of a patient’s
CMR led to CABG in 5% of cases and led to the avoidance
of CABG in 5% of cases. The impact of CMR on these pro-
cedures was principally based on LGE findings. The ab-
sence of viability led to avoidance of revascularization in
that arterial territory. Depending on the arterial territories
involved, this sometimes led to avoidance of revasculariza-
tion altogether or to switching from revascularization with
CABG to PCI. In patients being evaluated for cardiomy-
opathy of unknown etiology, the absence of LGE at a
young age (all less than 30 years old) without CAD risk
factors, and history or ECG evidence of MI, led to clini-
cians deciding to avoid coronary angiography [19].
Medication management was also significantly affected
by the results of CMR testing (Table 2). Systemic antico-
agulation was initiated in 6% of cases on account of
thrombus imaging on CMR, and systemic anticoagulation
was stopped in 6% of cases due to absence of thrombus
on CMR despite being suspected by echocardiography
(CMR was performed within 24 hours of the echo in
all of these cases). Other cardiac medications were
Figure 4 Change in diagnosis after performance of CMR. Weighted lines represent number of patients (also numerically represented within
the circle).
Table 2 Impact of CMR on patient management
Impact on catheter-based procedures 41 (27%)
Led to angiography 14 (9%)
Avoided angiography 17 (11%)
Led to biopsy 3 (2%)
Avoided biopsy 1 (1%)
Led to PCI 11 (7%)
Avoided PCI 8 (5%)
Impact on surgical revascularization 14 (10%)
Led to CABG 7 (5%)
Avoided CABG 7 (5%)
Impact on electrophysiology procedures 15 (10%)
Led to ICD 5 (3%)
Avoided ICD 10 (7%)
Impact on medications 25 (17%)
Started anticoagulation 9 (6%)
Stopped anticoagulation 9 (6%)
Started cardiac medication 4 (3%)
Stopped cardiac medication 3 (2%)
Hospital admission 2 (1%)
Hospital discharge 2 (1%)
PCI=Percutaneous coronary intervention; CABG=Coronary artery bypass
grafting; ICD=Implantable cardioverter-defibrillator.
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upon CMR findings.Significant clinical impact
There was a significant clinical impact in nearly two-thirds
of cases (65%) overall, which included a new diagnosis in
30% of cases and a change in management in 52% of cases
(Figure 5). A total of 17% of patients had both a new diag-
nosis and a change in management; however, in accordance
to our pre-defined categories, these patients were counted
only once toward our measurement of significant clinical
impact.
Gender (OR 2.31, 95% CI 1.17-4.58, p=0.02), LVEF
(OR 0.97, 95% CI 0.94-1.00, p=0.03) and LGE (OR
7.06, 95% CI 3.01-16.56, p<0.0001) were significant
univariable predictors of significant clinical impact. In
a multivariable model adjusting for clinical and imaging
parameters, only LGE (OR 6.72, 95% CI 2.56-17.60,
p=0.0001) independently predicted significant clinical
impact (Table 3).Discussion
To our knowledge, this is the first study systematically
investigating the clinical impact of CMR on manage-
ment and diagnosis in heart failure patients in daily
practice.
Figure 5 Significant Clinical Impact of CMR. On the basis of CMR
findings, 52% of patients had a change in management and 30% of
patients had a new diagnosis. In 17% of patients CMR resulted in
both a change in management and a new diagnosis. In total, CMR
had a significant clinical impact on 65% of patients.
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The EuroCMR registry was a multi-center registry that
followed 11,040 patients from 20 European centers and
sought to evaluate indications, image quality, safety, and
impact on patient management of routine CMR [20]. The
investigators found that in 61.8% of patients, CMR had a
significant impact on management, pre-defined as findings
that had therapeutic consequence or led to an entirely
new diagnosis. In addition, the EuroCMR registry reported
discovery of a completely new diagnosis in 16.8% of cases.
However, there are important differences between our
study and the EuroCMR registry. Our study is the first to
look specifically at heart failure patients. The EuroCMR
registry performed subgroup analyses on patient age,Table 3 Predictors of significant clinical impact
UNIVARIABLE
Parameter Odds ratio 95% CI
Gender 2.31 1.17-4.58
Age 1.02 1.02-1.04
NYHA class 1.20 0.76-1.88
LVEF 0.97 0.94-1.00
Diabetes 1.31 0.61-2.81
Hypertension 1.71 0.81-3.63
Prior revascularization 1.84 0.93-3.63
LGE 7.06 3.01-16.56
Univariable and multivariable associations of clinical and imaging parameters with
LVEF = Left Ventricular Ejection Fraction, LGE = Late Gadolinium Enhancement, CI =indication, and the performance of stress testing; however,
no specific analysis was performed on heart failure pa-
tients or those with depressed LVEF. Within our study, all
patients had previously undergone testing with echocardi-
ography, whereas in the EuroCMR registry, CMR was the
first test performed in 23.1% of patients. Importantly, in
our study we examined the clinical and CMR variables
which were most predictive of significant clinical impact
using multivariable modeling. Another difference between
the two registries was that the EuroCMR study included
patients undergoing stress testing (in 20.9% of cases). We
did not include stress CMR in this study because it is cur-
rently significantly less available and we wanted the study
results to be as widely applicable as possible. It is possible
that inclusion of stress CMR would lead to greater impact
on heart failure patient management. In our study we
attempted to reduce bias in interpretation of what consti-
tutes “significant clinical impact” by using additional inde-
pendent physician interpreters who were unaffiliated with
the CMR program. Finally, in contrast to the EuroCMR
registry, our study sheds specific light on the effects of
CMR within the context of the US healthcare system.
Implications
Currently many physicians reserve the use of CMR in
heart failure only for a small subset of ‘boutique’ indica-
tions. Guidelines from the Heart Failure Society of America
recommends the use of CMR in the diagnosis of amyloid-
osis, sarcoidosis, hemochromatosis, and possibly in viability
assessment [12]. However, an increasing amount of data
has emerged suggesting that CMR is an effective initial test
in the evaluation of patients presenting with heart failure
[1,2,19]. Our observations lend support to this notion.
Our study shows that CMR has significant clinical impact
in this population despite universal use of prior echocardi-
ography. Given its accessibility and low cost, we believe that
echocardiography remains an essential first-line test in
these patients. Our purpose was not to compare theMULTIVARIABLE
P-value Odds ratio 95% CI P-value
0.02 1.16 0.51-2.61 0.72
0.10 1.01 0.99-1.04 0.32
0.44 0.73 0.41-1.28 0.27
0.03 0.98 0.95-1.10 0.23
0.48 1.22 0.48-3.10 0.67
0.16 0.87 0.30-2.59 0.81
0.08 0.89 0.36-2.21 0.80
<0.0001 6.72 2.56-17.60 0.0001
subsequent significant clinical impact. NYHA = New York Heart Association,
Confidence Interval.
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http://jcmr-online.com/content/15/1/89diagnostic ability of echocardiography with CMR but
rather to assess the additive clinical value of CMR in
heart failure patients that underwent standard diagnostic
evaluations (which invariably included echo). However,
further studies are needed to support such an approach.
In particular, there is a need for larger, multi-center studies
that evaluate not only significant clinical impact, but also
outcomes and cost-effectiveness.Limitations
Our study was limited by a small sample size (150 patients)
drawn from a single academic tertiary center. As a result,
there was undoubtedly significant selection bias present
and the patient group may not be representative of the
wider heart failure population. For example, the mean age
of our study population was 54 years, which is significantly
younger than that reported in the community [21]. Further-
more, it is probable that clinicians selected patients that
were more likely to benefit from CMR. This is consistent
with the observation that the total number of patients
referred for CMR in this study represents only a small
proportion (approximately 30%) of the overall popula-
tion with heart failure and depressed LVEF passing
through the heart failure program during the study
period.
Another important limitation is that this study was not
designed to test the validity of the management decisions
or new diagnoses, which occurred as a result of the CMR.
A change in management or a new diagnosis may not
necessarily equate to improved outcomes. This study was
not designed to test the evidence base on which clinicians
made management decisions. For example, two recent
studies have questioned the value of revascularization
in patients with ischemic cardiomyopathy [22,23]. It is
also possible that CMR driven changes in management
and new diagnoses resulted in further testing and/or
procedures downstream, some of which may be associated
with their own inherent risks. To address these questions,
future randomized prospective studies are needed to com-
pare outcomes between a CMR guided vs conventional
approach in heart failure patients.
In this study, patient treatment was entirely at the
discretion of the patient’s cardiologist and, therefore,
there may be significant management differences between
individuals that impacted the results. Our study did not
analyze cost-effectiveness of CMR as compared to current
testing in the heart failure population. Cost-effectiveness
analyses will be needed to better define the possible bene-
fits of CMR in the management of heart failure. Although
it maybe argued that interpretation of “significant clinical
impact,” in our study was subjective, we attempted to
minimize this by predefining all categories and using
several independent interpreters.Lastly, it is important to realize that there are limitations
to the use of CMR in heart failure patients. These include
the additional costs of the procedure, long scan times, as
well as difficulties in scanning individuals with claustropho-
bia and severe orthopnea. In addition, a significant portion
of heart failure patients have relative or absolute contrain-
dications to CMR, including severe renal impairment and
implanted devices such as pacemakers, defibrillators and
ventricular assist devices.
Conclusions
CMR makes a significant impact on clinical management,
decision-making and diagnosis in 65% of selected heart
failure patients. This additive impact was seen despite
universal use of prior echocardiography in this patient
group. Our study lends support to the growing use of
CMR in the assessment of heart failure patients.
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